Login to Your Account

Orphan Space Serving NPS Well

Days Ahead of PDUFA Date Gattex Wins Approval in SBS

By Jennifer Boggs
Managing Editor

Wednesday, December 26, 2012
It may have taken more than two decades, but NPS Pharmaceuticals Inc. is set to launch its first commercial product in the first quarter, following Friday's FDA approval of Gattex (teduglutide [rDNA origin]) as a long-term treatment for short bowel syndrome (SBS).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription